Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00370331 · OUTCOME

Percentage of Participants With a Reduction in Use of Baseline ITP Medication

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
From Day 1 through Week 26 on-treatment

What was measured

Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use

Analysis population: ITT Population

Groups in this outcome

Placebo

Matching placebo tablets taken once a day

Eltrombopag 50 mg QD

Eltrombopag 50 mg oral tablets taken once a day (QD)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo60
Eltrombopag 50 mg QD134

Reported measurements

Participants who reduced/discontinued ITP therapy
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Placebo32Not reportedNot reportedNot reportedNot reported
Eltrombopag 50 mg QD59Not reportedNot reportedNot reportedNot reported
Participants not reducing/discont. ITP therapy
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Placebo68Not reportedNot reportedNot reportedNot reported
Eltrombopag 50 mg QD41Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        32
      2. group Id
        OG001
        value
        59
    title
    Participants who reduced/discontinued ITP therapy
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        68
      2. group Id
        OG001
        value
        41
    title
    Participants not reducing/discont. ITP therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    2. group Id
      OG001
      value
      134
    units
    Participants
description
Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use
groups
  1. description
    Matching placebo tablets taken once a day
    id
    OG000
    title
    Placebo
  2. description
    Eltrombopag 50 mg oral tablets taken once a day (QD)
    id
    OG001
    title
    Eltrombopag 50 mg QD
param Type
NUMBER
population Description
ITT Population
reporting Status
POSTED
time Frame
From Day 1 through Week 26 on-treatment
title
Percentage of Participants With a Reduction in Use of Baseline ITP Medication
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice